Group 1 - The core point of the article is that Anglikon has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of July 31 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio in the diabetes treatment market [2]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

近半年该股累计上榜龙虎榜10次，上榜次日股价平均涨1.76%，上榜后5日平均涨2.58%。 资金流向方面，今日该股主力资金净流入1.87亿元，其中，特大单净流入1.63亿元，大单资金净流入 2425.75万元。近5日主力资金净流入879.32万元。（数据宝） 昂利康今日涨停，全天换手率11.32%，成交额11.65亿元，振幅8.87%。龙虎榜数据显示，机构净买入 1.72亿元，营业部席位合计净卖出2060.64万元。 深交所公开信息显示，当日该股因日涨幅偏离值达11.39%上榜，机构专用席位净买入1.72亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.07亿元，其中，买入成交额为2.29亿 元，卖出成交额为7742.32万元，合计净买入1.52亿元。 具体来看，今日上榜的营业部中，共有6家机构专用席位现身，即买一、买二、买三、买四、买五、卖 一、卖五，合计买入金额2.05亿元，卖出金额3235.10万元，合计净买入1.72亿元。 昂利康7月31日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | ...

7月31日，昂利康公告，公司获得国家药品监督管理局核准签发的西格列汀二甲双胍缓释片《药品注册 证书》。西格列汀二甲双胍缓释片为复方制剂，适用于正在接受西格列汀和二甲双胍缓释片联合治疗的 成人2型糖尿病患者。公司于2024年1月获得西格列汀二甲双胍缓释片药品上市许可申请受理通知书，并 于近日获得国家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》视同通过一致性评 价。 ...

Group 1 - The company, Anglikang (002940.SZ), has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [1] - Sitagliptin Metformin Extended-Release Tablets are a compound preparation suitable for adult patients with type 2 diabetes who are currently receiving combined treatment with Sitagliptin and Metformin Extended-Release Tablets [1]

| 买入金额最大的前5名 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 交易营业部名称 | | | 买入金额(万) | 占总成交比例 | 卖出金额(万) | 占总成交比例 | 净额(万)® | | 1 | 机构专用 | 1414次 43.42% | 0 | 8269.79 | 7.10% | 0.00 | 0.00% | 8269 79 | | 2 | 机构专用 | 1414次 43 42% | ▶ | 3797.68 | 3.26% | 126.59 | 0.11% | 3671.09 | | 3 | 机构专用 | 1414次 43.42% | A | 3490.92 | 3.00% | 1960.58 | 1.68% | 1530.34 | | 4 | 机构专用 | 1414次 43.42% | | 2990.94 | 2.57% | 0.00 | 0.00% | 2990.94 | | 5 | 机构专用 | 1414次 43.42% | ▶ | 1913.61 | 1.64% | 0.00 ...

（文章来源：智通财经） 昂利康今日涨停，成交额11.65亿元，换手率11.32%，盘后龙虎榜数据显示，5家机构专用席位净买入 1.84亿元，有1家机构专用席位净卖出1147.94万元。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its product, Sitagliptin Metformin Extended-Release Tablets, indicating a significant regulatory milestone for the company in the diabetes treatment market [1] Group 1 - The Sitagliptin Metformin Extended-Release Tablets are a compound formulation designed for adult patients with type 2 diabetes who are currently undergoing treatment with both Sitagliptin and Metformin Extended-Release Tablets [1]

Core Viewpoint - The company has received the drug registration certificate for the combination drug Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, which is intended for adult patients with type 2 diabetes currently undergoing treatment with both Sitagliptin and Metformin Extended-Release Tablets [1] Group 1 - The drug is a compound formulation suitable for adult patients with type 2 diabetes [1] - The company received the drug marketing license application acceptance notice in January 2024 and has recently obtained approval from the National Medical Products Administration [1] - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which will further enrich the company's product pipeline [1] Group 2 - There is significant uncertainty regarding the specific sales performance of the newly approved drug [1]

格隆汇7月31日丨昂利康(002940.SZ)公布，近日，浙江昂利康制药股份有限公司收到国家药品监督管理 局签发的西格列汀二甲双胍缓释片《药品注册证书》。西格列汀二甲双胍缓释片为复方制剂，适用于正 在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。 ...